ClinicalTrials.gg
CompletedNCT03901339TROPiCS-02Updated Oct 21, 2024Results posted

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

A Phase 3 interventional study of Sacituzumab Govitecan-hziy and Eribulin in Metastatic Breast Cancer, sponsored by Gilead Sciences. Completed at 113 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
543
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing sacituzumab govitecan in Breast Neoplasms — 16 open to participants now, 24 under way, 4 of them phase 3. sacituzumab govitecan · Breast Neoplasms.

Enrollment
4th of 27
543 · median 75
Started
2019
with 2 others
Phase 3
6 of 27
1 open now
Registered
4th of 27
by date
Lead sponsor
5 of 27
Gilead Sciences

Among the 27 studies testing sacituzumab govitecan in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 27 studies testing sacituzumab govitecan in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sacituzumab govitecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented evidence of hormone receptor-positive human epidermal growth factor receptor 2 negative (-negative) (hormonal receptor-positive (HR+)/HER2-) breast cancer (MBC) confirmed.
  • to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for metastatic disease:

    • At least 1 taxane in any setting.
    • At least 1 prior anticancer hormonal treatment in any setting.
    • At least 1 cyclin-dependent kinase inhibitor 4/6 in any setting.
  • Eligible for one of the chemotherapy options listed in the TPC arm.
  • Documented disease progression after the most recent therapy.
  • Adequate bone marrow function ( ≥ 9 g/dL, (ANC) ≥ 1,500 per mm\^3, ≥ 100,000 per mm\^3).
  • Adequate renal function: calculated ≥ 30 mL/minute according to the Cockcroft and Gault formula .
  • Adequate liver function ( ≤ 1.5 institutional (IULN), or ≤ 3 IULN for individuals with documented Gilbert's syndrome, (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x IULN (in the case of liver metastases ≤ 5.0 x IULN)).
  • Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin (ß-hCG)).

Key Exclusion Criteria:

  • Previous treatment with topoisomerase 1 Inhibitors as a free form or as other formulations.
  • History of significant cardiovascular disease or (ECG) abnormality.
  • Active serious infection requiring antibiotics.
  • Any medical or other condition which, in the opinion of the Investigator, causes the individual to be medically unfit to receive sacituzumab govitecan or unsuitable for any reason.
  • Locally advanced MBC (stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
543 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy

    Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy

  • Active comparator
    Treatment of Physician's Choice (TPC)

    Participants will receive TPC determined prior to randomization from one of the following single-agent treatment: Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic) * Eribulin: 1.4 mg/m\^2 for North American sites, 1.23 mg/m\^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle * Capecitabine: 1000-1250 mg/m\^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle * Gemcitabine: 800-1200 mg/m\^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution * Vinorelbine: 25 mg/m\^2 via IV on Day 1 weekly cycle per institution

    Drug: Eribulin · Drug: Capecitabine · Drug: Gemcitabine · Drug: Vinorelbine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment

    PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to BICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Disease progression was defined as an increase of greater than 20% in the sum of the longest diameter (LD) of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

    Time frame: Up to 42.8 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. OS was estimated using Kaplan-Meier estimate. Participants without documentation of death were censored on the date they were last known to be alive.

    Time frame: Up to 42.8 months

  2. Objective Response Rate (ORR) by BICR and Local Investigator Review (LIR) Assessment

    ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR) that was confirmed at 4 weeks or later after initial response by BICR and LIR using RECIST 1.1. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.

    Time frame: Up to 42.8 months

  3. Duration of Response (DOR) by BICR and LIR Assessment

    DOR was defined as the time from the date a response of CR or PR was first documented until the date of the first documentation of disease progression or date of death (whichever occurred first). DOR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. DOR was estimated using Kaplan-Meier estimate.

    Time frame: Up to 42.8 months

  4. Clinical Benefit Rate (CBR) by BICR and LIR Assessment

    CBR was defined as the percentage of participants with the best overall response of CR, PR, or durable stable disease (duration of SD ≥ 6 months after randomization). CBR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. PD: Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions.

    Time frame: Up to 42.8 months

  5. PFS by LIR Assessment

    PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to LIR using RECIST 1.1. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

    Time frame: Up to 42.8 months

  6. Time to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30)

    TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the global health status/QoL scale.The EORTC QLQ-C30 is a 30-item questionnaire to assess QoL of cancer patients. It has 5 functional scales(physical,role,emotional,cognitive, social)1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). Participant responses to global health status,'How would you rate your overall health during the past week?' (Item 29)and the QoL 'How would you rate your overall quality of life during the past week?'(Item 30)questions were scored on 7-point scale (1=very poor; 7=excellent). All scales and single-item measures range in score from 0 to 100. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores for GHS show a better level of functioning.

    Time frame: Up to 37.8 months

  7. TTD of Pain Score as Measured by EORTC QLQ-C30

    TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the pain score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Participant responses to 2 questions about pain, 'Have you had pain' and 'Did pain interfere with your daily activities' were scored on 4-point scale (1=not at all;4=very much). Summed raw scores were standardized by linear transformation so that scores ranges from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).

    Time frame: Up to 37.8 months

  8. TTD of Fatigue Score as Measured by EORTC QLQ-C30

    TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the fatigue score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties).All of the scales and single-item measures range in score from 0 to 100.Participant responses to 3 questions about fatigue 'Did you need to rest', 'Have you felt weak' and 'Were you tired' were scored on a 4-point scale (1=not at all;4=very much).Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).

    Time frame: Up to 37.8 months

  9. Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a subject administered a medicinal product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of the study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: Up to 43.4 months

  10. Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs)

    Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above

    Time frame: Up to 43.4 months

  11. Percentage of Participants Who Experienced the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline

    Blood samples were collected for hematology, serum chemistry, and the laboratory abnormalities were assessed. A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days.The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.

    Time frame: Up to 43.4 months

  12. Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - Shift From Baseline Value to Best Value During Treatment

    ECOG performance status (PS) measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease performance without restriction;1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;2=Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours;3=Capable of only limited self-care;confined to bed or chair more than 50% of waking hours;4=Completely disabled; cannot carry on any self-care; totally confined to bed or chair;5=Dead. Lower score indicated good performance status. Percentage of participants with Baseline ECOG PS score and corresponding changes to the best values post-baseline have been reported.

    Time frame: Up to 43.4 months

07

Results

Posted Oct 21, 2024

Participant flow

Participants were enrolled at study sites in Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Started272271
Received at least 1 dose of study drug268249
Completed00
Not completed272271
Withdrew: Death220192
Withdrew: Informed consent withdrawn1340
Withdrew: Sponsor request3023
Withdrew: Reason not specified57
Withdrew: Lost to follow-up47
Withdrew: Covid1902

Outcome measures

PrimaryProgression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment

PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to BICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Disease progression was defined as an increase of greater than 20% in the sum of the longest diameter (LD) of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

Time frame:
Up to 42.8 months
Reported as:
Median · months
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment5.5 (4.2 to 6.9)4.0 (3.0 to 4.4)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.653 · 95% CI 0.526 to 0.812
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. OS was estimated using Kaplan-Meier estimate. Participants without documentation of death were censored on the date they were last known to be alive.

Time frame:
Up to 42.8 months
Reported as:
Median · months
Overall Survival (OS)
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Overall Survival (OS)14.5 (13.0 to 16.0)11.2 (10.2 to 12.6)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0133 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis, and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.788 · 95% CI 0.652 to 0.952
SecondaryObjective Response Rate (ORR) by BICR and Local Investigator Review (LIR) Assessment

ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR) that was confirmed at 4 weeks or later after initial response by BICR and LIR using RECIST 1.1. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.

Time frame:
Up to 42.8 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by BICR and Local Investigator Review (LIR) Assessment
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
ORR by BICR Assessment21.3 (16.6 to 26.7)14.0 (10.1 to 18.7)
ORR by LIR Assessment16.5 (12.3 to 21.5)9.2 (6.1 to 13.3)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = 0.0268 · Odds ratio (or): 1.662 · 95% CI 1.058 to 2.609
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = 0.0098 · Odds ratio (or): 1.989 · 95% CI 1.174 to 3.369
SecondaryDuration of Response (DOR) by BICR and LIR Assessment

DOR was defined as the time from the date a response of CR or PR was first documented until the date of the first documentation of disease progression or date of death (whichever occurred first). DOR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. DOR was estimated using Kaplan-Meier estimate.

Time frame:
Up to 42.8 months
Reported as:
Median · months
Duration of Response (DOR) by BICR and LIR Assessment
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
DOR by BICR Assessment8.1 (6.7 to 8.9)5.6 (3.8 to 7.9)
DOR by LIR Assessment7.0 (5.6 to 8.9)4.3 (4.2 to 6.1)
SecondaryClinical Benefit Rate (CBR) by BICR and LIR Assessment

CBR was defined as the percentage of participants with the best overall response of CR, PR, or durable stable disease (duration of SD ≥ 6 months after randomization). CBR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. PD: Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions.

Time frame:
Up to 42.8 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) by BICR and LIR Assessment
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
CBR by BICR Assessment33.8 (28.2 to 39.8)22.1 (17.3 to 27.6)
CBR by LIR Assessment32.4 (26.8 to 38.3)21.0 (16.3 to 26.4)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = 0.0025 · Odds ratio (or): 1.796 · 95% CI 1.227 to 2.628
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = 0.0024 · Odds ratio (or): 1.834 · 95% CI 1.237 to 2.717
SecondaryPFS by LIR Assessment

PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to LIR using RECIST 1.1. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

Time frame:
Up to 42.8 months
Reported as:
Median · months
PFS by LIR Assessment
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
PFS by LIR Assessment4.3 (3.8 to 5.4)3.1 (2.7 to 4.0)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0010 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis, and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.728 · 95% CI 0.602 to 0.881
SecondaryTime to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30)

TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the global health status/QoL scale.The EORTC QLQ-C30 is a 30-item questionnaire to assess QoL of cancer patients. It has 5 functional scales(physical,role,emotional,cognitive, social)1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). Participant responses to global health status,'How would you rate your overall health during the past week?' (Item 29)and the QoL 'How would you rate your overall quality of life during the past week?'(Item 30)questions were scored on 7-point scale (1=very poor; 7=excellent). All scales and single-item measures range in score from 0 to 100. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores for GHS show a better level of functioning.

Time frame:
Up to 37.8 months
Reported as:
Median · months
Time to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30)
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Time to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30)4.3 (3.1 to 5.7)3.0 (2.2 to 3.9)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0059 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis, and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.751 · 95% CI 0.612 to 0.922
SecondaryTTD of Pain Score as Measured by EORTC QLQ-C30

TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the pain score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Participant responses to 2 questions about pain, 'Have you had pain' and 'Did pain interfere with your daily activities' were scored on 4-point scale (1=not at all;4=very much). Summed raw scores were standardized by linear transformation so that scores ranges from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).

Time frame:
Up to 37.8 months
Reported as:
Median · months
TTD of Pain Score as Measured by EORTC QLQ-C30
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
TTD of Pain Score as Measured by EORTC QLQ-C303.8 (2.8 to 5.0)3.5 (2.8 to 5.0)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.4151 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis, and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.918 · 95% CI 0.748 to 1.126
SecondaryTTD of Fatigue Score as Measured by EORTC QLQ-C30

TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the fatigue score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties).All of the scales and single-item measures range in score from 0 to 100.Participant responses to 3 questions about fatigue 'Did you need to rest', 'Have you felt weak' and 'Were you tired' were scored on a 4-point scale (1=not at all;4=very much).Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).

Time frame:
Up to 37.8 months
Reported as:
Median · months
TTD of Fatigue Score as Measured by EORTC QLQ-C30
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
TTD of Fatigue Score as Measured by EORTC QLQ-C302.2 (1.6 to 2.8)1.4 (1.1 to 1.9)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0021 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: prior chemotherapy regimens for metastatic disease, presence of visceral metastasis, and endocrine therapy in the metastatic setting for at least 6 months.) · Hazard ratio (hr): 0.732 · 95% CI 0.598 to 0.894
SecondaryPercentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a subject administered a medicinal product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of the study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.

Time frame:
Up to 43.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)100.096.0
SecondaryPercentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs)

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above

Time frame:
Up to 43.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs)
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs)27.619.3
SecondaryPercentage of Participants Who Experienced the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline

Blood samples were collected for hematology, serum chemistry, and the laboratory abnormalities were assessed. A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days.The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.

Time frame:
Up to 43.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Alanine Aminotransferase Increased1.12.1
Hypoalbuminemia00.4
Alkaline Phosphatase Increased00.8
Aspartate Aminotransferase Increased1.51.3
Bilirubin Increased2.30.8
Creatinine Increased0.41.7
Creatinine Clearance Decreased2.31.3
Hypoglycemia1.10.8
Hypermagnesemia0.40
Hypomagnesemia0.80
Hyperkalemia1.90
Hypokalemia4.20.4
Hyponatremia0.80.4
Anemia7.55.0
Hemoglobin Increased1.10
Leukocytes Decreased38.925.7
Leukocytosis0.40.4
Lymphocytes Decreased21.513.7
Lymphocytes Increased1.92.1
Neutrophils Decreased53.240.2
Platelets Decreased1.93.7
SecondaryPercentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - Shift From Baseline Value to Best Value During Treatment

ECOG performance status (PS) measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease performance without restriction;1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;2=Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours;3=Capable of only limited self-care;confined to bed or chair more than 50% of waking hours;4=Completely disabled; cannot carry on any self-care; totally confined to bed or chair;5=Dead. Lower score indicated good performance status. Percentage of participants with Baseline ECOG PS score and corresponding changes to the best values post-baseline have been reported.

Time frame:
Up to 43.4 months
Reported as:
Number · percentage of participants
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - Shift From Baseline Value to Best Value During Treatment
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Baseline ECOG 0, During Treatment ECOG 034.938.7
Baseline ECOG 0, During Treatment ECOG 17.88.9
Baseline ECOG 0, During Treatment ECOG 200.4
Baseline ECOG 1, During Treatment ECOG 019.411.5
Baseline ECOG 1, During Treatment ECOG 136.438.3
Baseline ECOG 1, During Treatment ECOG 21.62.1

Adverse events

Collected over Adverse Events and All-Cause Mortality: Up to 43.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacituzumab Govitecan234/272 (86%)74/268 (27.6%)264/268 (98.5%)
Treatment of Physician's Choice (TPC)238/271 (87.8%)48/249 (19.3%)234/249 (94%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventSacituzumab GovitecanTreatment of Physician's Choice (TPC)
DiarrhoeaGastrointestinal disorders13/2681/249
Febrile neutropeniaBlood and lymphatic system disorders11/26810/249
NeutropeniaBlood and lymphatic system disorders8/2682/249
Abdominal painGastrointestinal disorders6/2680/249
NauseaGastrointestinal disorders2/2685/249
PneumoniaInfections and infestations4/2685/249
Neutropenic colitisGastrointestinal disorders5/2680/249
VomitingGastrointestinal disorders5/2682/249
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2684/249
ColitisGastrointestinal disorders4/2681/249
Most frequent other events
Showing 10 of 54
Most frequent other events
EventSacituzumab GovitecanTreatment of Physician's Choice (TPC)
NeutropeniaBlood and lymphatic system disorders184/268134/249
DiarrhoeaGastrointestinal disorders163/26857/249
NauseaGastrointestinal disorders157/26886/249
AlopeciaSkin and subcutaneous tissue disorders128/26846/249
FatigueGeneral disorders106/26881/249
AnaemiaBlood and lymphatic system disorders97/26868/249
ConstipationGastrointestinal disorders93/26861/249
VomitingGastrointestinal disorders63/26839/249
AstheniaGeneral disorders62/26849/249
Decreased appetiteMetabolism and nutrition disorders57/26852/249

Baseline characteristics

The Intent-to-Treat (ITT) Population included all participants who were randomized, regardless of whether they received study treatment or not.

Age, Categorical
Age, Categorical(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
<=18 years000
Between 18 and 65 years199204403
>=65 years7367140
Age, Continuous
Age, Continuous(years)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
Mean57 ± 11.556 ± 10.456 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
Female270268538
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
Hispanic or Latino61218
Not Hispanic or Latino222204426
Unknown or Not Reported445599
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
Race — White184178362
Race — Unknown or Not Reported6970139
Race — Black or African American81321
Race — Asian11516
Race — Other or More Than One Race044
Race — Native Hawaiian or Other Pacific Islander011
Region of Enrollment
Region of Enrollment(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total~(N=543)
United States115113228
France6473137
Spain353469
Germany202646
Belgium16925
Italy9615
United Kingdom7714
Netherlands628
Canada011
08

Study locations

113 sites
  • HonorHealth Research Institute
    Avondale, Arizona 85392, United States
  • Arizona Oncology Associates, PC
    Tucson, Arizona 85704, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • University of California, San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Los Angeles Hematology Oncology Medical Group
    Los Angeles, California 90017, United States
  • UCLA Department of Medicine - Hematology/Oncology
    Los Angeles, California 90095, United States
  • University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94115, United States
  • Rocky Mountain Cancer Centers
    Aurora, Colorado 80012, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Yale University Cancer Center
    New Haven, Connecticut 06520, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • University of Miami - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University - Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northside Hospital, Inc.
    Atlanta, Georgia 30342, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Mercy Medical Center, Medical Oncology & Hematology
    Baltimore, Maryland 21202, United States
  • Maryland Oncology Hematology, P.A.
    Rockville, Maryland 20850, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Allina Health, Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine - Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Laura and Isaac Perlmutter Cancer Center/NYU Langone Health
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • The West Clinic, PC dba West Cancer Center
    Germantown, Tennessee 38138, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
    Dallas, Texas 75390, United States
  • Texas Oncology-Denton South
    Denton, Texas 76210, United States
  • Houston Methodist Hospital/Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology-Longview Cancer Center
    Longview, Texas 75601, United States
  • UT Health San Antonio - Mays Cancer Center
    San Antonio, Texas 78229, United States
  • Virginia Cancer Specialists
    Arlington, Virginia 22205, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc. DBA Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Chirec Cancer Institute
    Brussels, Belgium
  • Institut Jules Bordet
    Brussels, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
  • CHU UCL Namur/Site Sainte Elisabeth
    Namur, Belgium
  • Nova Scotia Cancer Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • Centre Hospitalier de L'Universite de Montreal - Hôpital Notre-Dame
    Montréal, Canada
  • Centre Hospitalier Universitaire de Sherbrooke - Fleurimont
    Sherbrooke, Canada
  • Hopital de Mercy
    Ars-Laquenexy, 57245, France
  • Institut Sainte Catherine
    Avignon, 84918, France
  • Hôpital Jean-Minjoz
    Besançon, 25030, France
  • Centre Georges-Francois Leclerc
    Dijon, 21000, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Institut Régional du Cancer de Montpellier
    Montpellier, 34298, France
  • Institut Curie
    Paris, 75005, France
  • Hospices Civils de Lyon
    Pierre-Bénite, 69310, France
  • Institut de Cancérologie Lucien Neuwirth
    Saint-Priest-en-Jarez, 42271, France
  • Institut Claudius Regaud
    Toulouse, 31300, France
  • HELIOS Klinikum Berlin-Buch
    Berlin, 13125, Germany
  • Gynakologisches Zentrum Bonn
    Bonn, 53111, Germany
  • Marienhospital Bottrop
    Bottrop, 46236, Germany
  • Städtisches Klinikum Dessau
    Dessau, 06847, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Kliniken Essen-Mitte
    Essen, 45136, Germany
  • Centrum für Hämatologie und Onkologie Bethanien
    Frankfurt, 60389, Germany
  • Onkologische Schwerpunktpraxis Eppendorf
    Hamburg, 20249, Germany
  • Gynakologisch-Onkologische Praxis Hannover
    Hannover, 30177, Germany
  • DIAKOVERE Krankenhaus gGmbH Henriettenstift - Standort Kirchrode
    Hannover, Germany
  • Nationales Centrum für Tumorerkrankungen - Heidelberg
    Heidelberg, 69120, Germany
  • Praxisklinik für Hämatologie und Onkologie Koblenz
    Koblenz, 56068, Germany
  • Universitätsmedizin Mannheim
    Mannheim, 68167, Germany
  • Klinikum Mutterhaus der Borromäerinnen
    Trier, Germany
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, Italy
  • Ospedale di Desio
    Desio, 20832, Italy
  • Ospedale Vito Fazzi di Lecce
    Lecce, Italy
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Azienda Ospedaliera San Gerardo di Monza
    Monza, Italy
  • Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto
    Piacenza, 29121, Italy
  • IFO Istituto Nazionale dei Tumori Regina Elena
    Rome, 00144, Italy
  • Antoni van Leeuwenhoekziekenhuis
    Amsterdam, 1066, Netherlands
  • Medisch Centrum Haaglanden Antoniushove
    Leidschendam, Netherlands
  • Maastricht UMC+
    Maastricht, 6229, Netherlands
  • Complejo Hospitalario Universitario A Coruna
    A Coruña, 15006, Spain
  • Hospital Quirónsalud Barcelona Instituto Oncologico Baselga
    Barcelona, 08023, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 08041, Spain

Showing the first 100 of 113 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E, Dalenc F, Gomez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23. PubMed 37633306 ↗
  • Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26. PubMed 36027558 ↗
  • Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marme F, Hong Q, Delaney RJ, Hafeez A, Andre F, Schmid P. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020 Apr;16(12):705-715. doi: 10.2217/fon-2020-0163. Epub 2020 Mar 30. PubMed 32223649 ↗
  • Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marme F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Oncologist. 2024 Sep 6;29(9):768-779. doi: 10.1093/oncolo/oyae088. Erratum In: Oncologist. 2025 Mar 10;30(3):oyae370. doi: 10.1093/oncolo/oyae370. PubMed 38748596 ↗
  • Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Spears PA, Tolaney SM. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative). Future Oncol. 2024 Apr;20(11):635-651. doi: 10.2217/fon-2023-0845. Epub 2024 Jan 25. PubMed 38270051 ↗
  • Rugo HS, Bardia A, Tolaney S. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3. No abstract available. PubMed 39067902 ↗
  • McCann KE, Hurvitz SA. Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):34-47. doi: 10.1097/GCO.0000000000000671. PubMed 33093337 ↗
  • Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020 Dec;31(12):1709-1718. doi: 10.1016/j.annonc.2020.09.004. Epub 2020 Sep 15. PubMed 32946924 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2023, 53 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 53 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
Apr 3, 2019
StartActual
May 8, 2019
Primary completionActual
Oct 20, 2023
CompletionActual
Oct 20, 2023
Results first posted
Oct 21, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03901339
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
May 8, 2019
Primary completion
Oct 20, 2023
Completion
Oct 20, 2023
Results posted
Oct 21, 2024
Last update
Oct 21, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion